Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells.
about
Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meetingSpotlight on elotuzumab in the treatment of multiple myeloma: the evidence to dateTreatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumabElotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.Targeting plasma cells: are we any closer to a panacea for diseases of antibody-secreting cells?Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.DNAM-1 controls NK cell activation via an ITT-like motif.Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.The extracellular interactome of the human adenovirus family reveals diverse strategies for immunomodulation.A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma.Dynamic Analysis of Human Natural Killer Cell Response at Single-Cell Resolution in B-Cell Non-Hodgkin Lymphoma.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.Mechanisms of Action and Clinical Development of Elotuzumab.Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors.Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.Signaling lymphocytic activation molecules Slam and cancers: friends or foes?Antibody dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab.Tolerogenic Transcriptional Signatures of Steady-State and Pathogen-Induced Dendritic Cells.Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
P2860
Q28075816-9321132F-4023-4042-B2C5-98A39BBFB13DQ28076147-906AF8ED-CEB9-4F69-B6C5-256DC4EFC069Q28078993-4D403501-8C92-4C36-8172-31C10ABE2883Q30249513-8FA3A10B-C83B-4C27-B545-B579C57E868AQ38672091-A024BB2F-87E2-4C2A-BA67-21272155D9BDQ38728585-8A7FA2A4-ACA0-4AC9-81E1-9B54B2BED90EQ38809499-1F4C026E-AD69-4CF3-8453-A15B89EA656AQ38820709-495CD20B-5CB7-410A-8666-023090A943B4Q38929980-BF44E20E-F71A-4C7B-B716-0A979D6B01C1Q39584752-DD900AEC-DD5A-47B1-8BB4-D4BD5438C488Q40244852-3FBE3ADC-EE43-4636-8CAF-5B7DB204B4BCQ40687723-A15F8437-6ABF-48B6-9663-F80A93CE9587Q47865755-04BF6918-3764-41B6-8F5D-B9CBC49E9930Q49237902-60C162F3-5458-4A38-826D-B1A94972E504Q49539698-EC0BCF12-D7F8-412E-AEEE-94F5165E9B5FQ49615618-D59E89E1-422F-48FB-812E-E4938198D49DQ49830211-CFF0B393-2658-4F52-A855-42D48266B943Q50026815-8576CDE6-7E13-4F25-8C45-868D850FCB08Q51325371-9FEB120C-9C8D-4EE5-96E3-4E68C5189A35Q52584346-2F7B4FF3-7888-49DE-92F6-3B516C253A9CQ52589219-749F77A9-BFF0-495D-BFE8-310B46A04CCBQ54255767-E959F5B8-105B-48A9-8636-F18F652FF781Q55310350-8B5A68B4-AE54-4260-9E94-C172EC6323F9Q59136966-DADD6F4D-6D8D-49C6-996C-EC111FF48BE4
P2860
Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Immune cell inhibition by SLAM ...... ive in multiple myeloma cells.
@en
Immune cell inhibition by SLAM ...... ive in multiple myeloma cells.
@nl
type
label
Immune cell inhibition by SLAM ...... ive in multiple myeloma cells.
@en
Immune cell inhibition by SLAM ...... ive in multiple myeloma cells.
@nl
prefLabel
Immune cell inhibition by SLAM ...... ive in multiple myeloma cells.
@en
Immune cell inhibition by SLAM ...... ive in multiple myeloma cells.
@nl
P2093
P2860
P356
P1476
Immune cell inhibition by SLAM ...... ive in multiple myeloma cells.
@en
P2093
André Veillette
Huaijian Guo
Mario-Ernesto Cruz-Munoz
Michael Robbins
P2860
P356
10.1128/MCB.01107-14
P407
P577
2014-10-13T00:00:00Z